Gain Therapeutics, Inc. — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 3/100
What the filing says
Gene Mack (CEO) and Gianluca Fuggetta (CFO/Principal Accounting Officer) certified the June 30, 2026 quarterly report on August 11, 2026, attesting that disclosure controls and internal controls over financial reporting are effective, financial statements fairly present the company's condition, and no material weaknesses or fraud involving management were identified. These are routine Sarbanes-Oxley compliance certifications required of all public companies.
Why this rating
Boilerplate SOX certification exhibits; no material facts, transactions, or control deficiencies disclosed. Standard compliance filing.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.